blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3158086

EP3158086 - BIOMARKERS FOR RESPONSE TO EZH2 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.02.2022
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  19.02.2021
FormerGrant of patent is intended
Status updated on  13.10.2020
FormerExamination is in progress
Status updated on  04.09.2020
FormerGrant of patent is intended
Status updated on  23.04.2020
FormerExamination is in progress
Status updated on  16.10.2019
FormerRequest for examination was made
Status updated on  24.03.2017
FormerThe international publication has been made
Status updated on  09.12.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
[2017/17]
Inventor(s)01 / LEVINE, Ross
1233 York Avenue Apartment 23a
New York, NY 10065 / US
02 / LAFAVE, Lindsay
303 East 71St Street Apt. 1e
New York, NY 10021 / US
03 / ABDEL-WAHAB, Omar
430 East 63rd Street Apt.7k
NewYork, NY 10065 / US
 [2017/17]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2021/12]
Former [2017/17]Atkinson, Jennifer
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
Application number, filing date15809484.719.06.2015
[2017/17]
WO2015US36677
Priority number, dateUS201462014594P19.06.2014         Original published format: US 201462014594 P
[2017/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015196064
Date:23.12.2015
Language:EN
[2015/51]
Type: A1 Application with search report 
No.:EP3158086
Date:26.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 23.12.2015 takes the place of the publication of the European patent application.
[2017/17]
Type: B1 Patent specification 
No.:EP3158086
Date:24.03.2021
Language:EN
[2021/12]
Search report(s)International search report - published on:US23.12.2015
(Supplementary) European search report - dispatched on:EP11.12.2017
ClassificationIPC:C12Q1/6886, A61K31/5377, G01N33/50
[2020/19]
CPC:
A61K31/5377 (EP,US); C12Q1/68 (IL); G01N33/5011 (EP,IL,KR,US);
G01N33/5748 (US); C12Q1/6886 (EP,IL,KR,US); C12Q2600/106 (EP,IL,KR,US);
C12Q2600/158 (EP,IL,KR,US); G01N2333/91017 (EP,IL,KR,US); G01N2333/948 (US);
G01N2800/7028 (EP,IL,KR,US) (-)
Former IPC [2017/17]C12Q1/68, G01N33/68, G01N33/574
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:BIOMARKER FÜR REAKTION AUF EZH2-HEMMER[2017/17]
English:BIOMARKERS FOR RESPONSE TO EZH2 INHIBITORS[2017/17]
French:BIOMARQUEURS DE LA REPONSE AUX INHIBITEURS D'EZH2[2017/17]
Entry into regional phase09.12.2016National basic fee paid 
09.12.2016Search fee paid 
09.12.2016Designation fee(s) paid 
09.12.2016Examination fee paid 
Examination procedure09.12.2016Examination requested  [2017/17]
09.12.2016Date on which the examining division has become responsible
13.07.2018Amendment by applicant (claims and/or description)
21.10.2019Despatch of a communication from the examining division (Time limit: M04)
02.03.2020Reply to a communication from the examining division
24.04.2020Communication of intention to grant the patent
03.09.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.10.2020Communication of intention to grant the patent
15.02.2021Fee for grant paid
15.02.2021Fee for publishing/printing paid
15.02.2021Receipt of the translation of the claim(s)
Opposition(s)04.01.2022No opposition filed within time limit [2022/10]
Fees paidRenewal fee
27.06.2017Renewal fee patent year 03
27.06.2018Renewal fee patent year 04
27.06.2019Renewal fee patent year 05
29.06.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.06.2015
AL24.03.2021
AT24.03.2021
CY24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
MK24.03.2021
MT24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
[2024/41]
Former [2024/22]HU19.06.2015
AL24.03.2021
AT24.03.2021
CY24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
MK24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2023/30]HU19.06.2015
AL24.03.2021
AT24.03.2021
CY24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2023/29]HU19.06.2015
AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2022/23]AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2022/18]AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
LU19.06.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
PT26.07.2021
IS24.12.2021
Former [2022/13]AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SI24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
PT26.07.2021
IS24.12.2021
Former [2022/10]AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
PT26.07.2021
IS24.12.2021
Former [2022/08]AL24.03.2021
AT24.03.2021
CZ24.03.2021
DK24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2022/07]AL24.03.2021
AT24.03.2021
CZ24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
MC24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2021/52]AT24.03.2021
CZ24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
PL24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2021/51]AT24.03.2021
CZ24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
IS24.07.2021
PT26.07.2021
Former [2021/50]AT24.03.2021
CZ24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
RO24.03.2021
RS24.03.2021
SE24.03.2021
SK24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
PT26.07.2021
Former [2021/48]AT24.03.2021
CZ24.03.2021
EE24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
RS24.03.2021
SE24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
Former [2021/46]AT24.03.2021
FI24.03.2021
HR24.03.2021
LT24.03.2021
LV24.03.2021
RS24.03.2021
SE24.03.2021
SM24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
Former [2021/38]FI24.03.2021
HR24.03.2021
LV24.03.2021
RS24.03.2021
SE24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
Former [2021/37]FI24.03.2021
HR24.03.2021
LV24.03.2021
RS24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
Former [2021/36]FI24.03.2021
HR24.03.2021
BG24.06.2021
NO24.06.2021
GR25.06.2021
Former [2021/35]FI24.03.2021
HR24.03.2021
NO24.06.2021
Former [2021/33]FI24.03.2021
NO24.06.2021
Cited inInternational search[A]WO9925373  (MILLENNIUM PHARM INC [US]);
 [XYA]WO2012144220  (ONCOTHERAPY SCIENCE INC [JP], et al);
 [YA]WO2013049770  (GLAXOSMITHKLINE LLC [US], et al);
 [XYA]US2014011696  (WIESNER THOMAS [US], et al);
by applicantUS548257
 US5322770
 US6004755
 US6218122
 US6218114
 US6271002
 US6329209
 US6365418
 US6379897
 US6451536
 US2003013208
 US2003077616
 WO03070887
 US6618679
 US2003199001
 US2003215858
 US6664377
 US6989262
 US7112408
 US7429466
 US7709198
 US2011251216
 US8068987
 WO2012144220
 WO2013049770
 WO2013138361
 US2014011696
 US8895245
 US9334527
 US9688665
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.